Imeik Technology Development Co., Ltd. Investment Quality Review (300896.SZ)
Investment View
Imeik has very high profitability, but 2025 revenue and profit decline make current price too high versus base FV. Current price is 91.63 CNY; conservative FV is 42.81 CNY; base FV is 62.64 CNY; price/base FV is 1.46; price/conservative FV is 2.14. This remains WATCHLIST: the company can be high quality or improving, but the price, conservative protection, or evidence quality does not yet satisfy the buy discipline.
The investment judgment is intentionally tied to the updated Chinese memo: rating Watch, source date 2026-07-04, and the refreshed source hash in frontmatter. The English memo keeps the same conclusion, not a more promotional interpretation of the company.
Business Quality
Imeik remains a high-margin medical-aesthetics consumables company, but the memo discounts it for 2025 revenue and profit decline, competition, and uncertainty around new products. Quality is not enough without better evidence of recovery.
The quality score in the Chinese source is carried through as evidence, but it is not allowed to override valuation. Brand power, network effects, channel depth, or software/platform economics matter only when they show up in repeatable free cash flow, capital allocation, and balance-sheet resilience.
Financial Audit
The audit frame uses the last five complete fiscal years in the Chinese source. Revenue, net income, OCF, capex, FCF, ROE, ROIC, FCF/revenue, and FCF/net income are treated as cross-checks rather than isolated proof. Cash, current financial assets, non-current financial assets, debt, minority interests, deferred tax, dilution, and contingent liabilities are kept separate in the balance-sheet bridge.
Dividends and buybacks are evidence for capital allocation and waiting return. They are not added again to fair value after cash flow and balance-sheet adjustments have already been counted.
Valuation
The valuation anchor is normalized FCF plus a conservative balance-sheet adjustment. The updated base case is 62.64 CNY; the conservative case is 42.81 CNY. The current quote of 91.63 CNY produces price/base FV of 1.46, which is the central signal gate.
The optimistic case is used only as an upside check. It does not upgrade the signal by itself. If normalized FCF, required multiple, or balance-sheet discounts deteriorate, base FV should be cut before relying on headline upside.
Buy And Tracking Discipline
A BUY would require either a lower price, a higher evidence-backed base FV, or both; the 2x discipline is not met unless price/base FV reaches 0.50 or better. For this memo the current action is WATCH.
Tracking should focus on repeatable FCF, revenue quality, margin trend, balance-sheet adjustments, shareholder-return coverage, and whether the specific business drivers described above are improving or weakening. Any future upgrade needs fresh evidence, not simply a higher market multiple.
Risk Controls
Risks are competition in fillers and aesthetics, product pipeline delays, regulation, channel inventory, lower procedure demand, and profitability reverting faster than expected. The position thesis should be reduced, delayed, or rejected if FCF/net income weakens without explanation, dividends exceed repeatable FCF, debt or contingent liabilities rise, financial assets need larger discounts, goodwill becomes impaired, or management actions dilute per-share value.
Evidence Boundary
This English memo is rewritten from the imported Chinese Markdown and preserves the same rating, current price, conservative FV, base FV, valuation discipline, and risk controls. Missing or unverifiable items remain caps on the signal. The memo does not convert WATCHLIST into BUY, does not soften AVOID, and does not use the optimistic case as the primary valuation anchor.
Data Sources
The Chinese report carries the detailed source trail for market quotes, five-year financial baselines, official filings or announcements, currency assumptions, and the risk-free-rate input. This English version keeps the investment reasoning aligned with that source file through sourceRel and sourceHash in frontmatter.
Research Boundary
This memo is for research only and is not personalized investment advice. It is an English research memo rewritten from the imported Chinese Markdown, with the same investment judgment, valuation anchors, risk controls, and follow-up discipline.